Skip to content

Study · Randomized controlled trial · 2019

7 results

Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.

Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Walzem RL, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB

Atherosclerosis5 Jul 2019Cited by 66 (Europe PMC)

PMID31326727 (opens in a new tab)DOI10.1016/j.atherosclerosis.2019.07.007 (opens in a new tab)PepBankPUB-31326727
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In a sub-group of patients starting liraglutide, LDL5 rebounded significantly during the wash-out period in an exploratory per-protocol analysis.

    In plain wordsIn an exploratory analysis of people who started liraglutide, small LDL particles rose again after the drug was stopped.

    Peptide
    Liraglutide
    Outcome
    IncreaseLDL5 rebound during wash-out (exploratory)
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeks per cross-over periodAs given in this study (human).

    Source sentences

    Summary
    Explorative analyses suggested that the subfraction LDL5 during the wash-out period rebounded significantly at least in a per-protocol analysis of the sub-group of patients starting the liraglutide therapy.
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out.
    Summary · context
    liraglutide/metformin vs. placebo/metformin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In statin-treated adults with coronary artery disease and newly diagnosed type 2 diabetes, liraglutide did not affect lipid subfractions overall compared with placebo.

    In plain wordsIn statin-treated adults with heart disease and new type 2 diabetes, liraglutide overall did not change cholesterol particle subfractions compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeLDL subfractions overall
    Study

    n: not reported in source

    Comparator
    Placebo (both arms with metformin)
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeks per cross-over periodAs given in this study (human).

    Source sentences

    Summary
    Overall, liraglutide did not affect lipid subfractions
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out.
    Summary · context
    liraglutide/metformin vs. placebo/metformin.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In statin-treated adults with coronary artery disease and newly diagnosed type 2 diabetes, liraglutide did not affect markers of low-grade inflammation overall compared with placebo.

    In plain wordsIn statin-treated adults with heart disease and new type 2 diabetes, liraglutide overall did not change inflammation markers compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMarkers of low-grade inflammation overall
    Study

    n: not reported in source

    Comparator
    Placebo (both arms with metformin)
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeks per cross-over periodAs given in this study (human).

    Source sentences

    Summary
    Overall, liraglutide did not affect lipid subfractions or markers of LGI compared to placebo.
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out.
    Summary · context
    liraglutide/metformin vs. placebo/metformin.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In statin-treated adults with coronary artery disease and newly diagnosed type 2 diabetes, the combination of liraglutide and metformin reduced total LDL subfractions; the abstract does not state the comparison.

    In plain wordsIn statin-treated adults with heart disease and new diabetes, liraglutide plus metformin lowered LDL particles; the comparator was not stated.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal LDL subfractions
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeks per cross-over periodAs given in this study (human).

    Source sentences

    Summary
    The combination of liraglutide and metformin reduced the total LDL subfractions
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out.
    Summary · context
    liraglutide/metformin vs. placebo/metformin.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In statin-treated adults with coronary artery disease and newly diagnosed type 2 diabetes, the combination of liraglutide and metformin reduced the most atherogenic subfraction LDL5; the abstract does not state the comparison.

    In plain wordsIn statin-treated adults with heart disease and new diabetes, liraglutide plus metformin lowered the most harmful small LDL particles; the comparator was not stated.

    Peptide
    Liraglutide
    Outcome
    DecreaseMost atherogenic LDL subfraction (LDL5)
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeks per cross-over periodAs given in this study (human).

    Source sentences

    Summary
    primarily by reducing the most atherogenic subfraction LDL5
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out.
    Summary · context
    liraglutide/metformin vs. placebo/metformin.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In statin-treated adults with coronary artery disease and newly diagnosed type 2 diabetes, the combination of liraglutide and metformin reduced CRP; the abstract does not state the comparison.

    In plain wordsIn statin-treated adults with heart disease and new diabetes, liraglutide plus metformin lowered CRP, an inflammation marker; the comparator was not stated.

    Peptide
    Liraglutide
    Outcome
    DecreaseC-reactive protein (CRP)
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeks per cross-over periodAs given in this study (human).

    Source sentences

    Summary
    and reduced CRP but not TNF-α.
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out.
    Summary · context
    liraglutide/metformin vs. placebo/metformin.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In statin-treated adults with coronary artery disease and newly diagnosed type 2 diabetes, liraglutide added to metformin did not reduce TNF-α.

    In plain wordsIn statin-treated adults with heart disease and new type 2 diabetes, liraglutide plus metformin did not lower TNF-α, an inflammation marker.

    Peptide
    Liraglutide
    Outcome
    No significant changeTumor necrosis factor-alpha (TNF-α)
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeks per cross-over periodAs given in this study (human).

    Source sentences

    Summary
    and reduced CRP but not TNF-α.
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out.
    Summary · context
    liraglutide/metformin vs. placebo/metformin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.